Share this article
TEL AVIV, Israel and LAUSANNE, Switzerland, Jan. 14, 2021 /PRNewswire/
Nucleai (www.Nucleaimd.com), a global provider in pathology-based biomarker discovery, and Debiopharm (www.debiopharm.com), a Swiss-based biopharmaceutical company specializing in drug development, announced that they have entered into a long-term collaboration to leverage Nucleai s artificial intelligence (AI) -powered biomarker research & discovery platform for one of Debiopharm s clinical stage oncology assets.
Having become one of Debiopharm s investment portfolio companies in 2020 (Series A), Nucleai s pathology-based platform analyzes tissue images using computer vision and machine learning methods to model the tumor and the immune system s spatial characteristics, creating unique and specific histological biomarkers that can predict patient response. These biomarkers allow further stratification of responder/non-responder patient populations, improve the success rate of clinical t